Last updated: February 27, 2026
What is NDC 00378-0222?
NDC 00378-0222 corresponds to Lisdexamfetamine dimesylate, marketed under the brand name Vyvanse. It is a central nervous system stimulant primarily prescribed for Attention Deficit Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED). Manufactured by Takeda Pharmaceuticals, Vyvanse holds a significant share of the ADHD medication market.
Market Size and Demographics
Current Market Overview
- The ADHD treatment market was valued at approximately $11 billion in 2022, with Vyvanse accounting for roughly 20% of the revenue share.
- Volume sales of Vyvanse in the U.S. reached $2.4 billion in 2022, with over 45 million prescriptions dispensed across the country.
- The global ADHD market is projected to grow at a compound annual growth rate (CAGR) of about 6.3% from 2023 to 2030**[1].
Demographic Trends
- The primary population includes children aged 6–17 years, representing roughly 8 million individuals diagnosed with ADHD in the U.S.
- Adult ADHD treatment accounts for 35% of Vyvanse prescriptions.
- Increasing diagnoses, coupled with off-label use, expand the market.
Competitive Landscape
Key Competitors
| Drug Name |
Manufacturer |
Strengths |
Market Share (2022) |
Price Range (per unit) |
| Vyvanse (Lisdexamfetamine) |
Takeda |
Long-acting, single daily dose |
20% |
$40–$60 |
| Adderall XR |
Teva, Allergan |
Short-acting, well-established |
25% |
$15–$30 |
| Concerta |
Janssen |
Extended-release, high compliance |
15% |
$35–$55 |
| Focalin XR |
Novartis |
Lower dose requirements, fewer side effects |
10% |
$30–$50 |
| Others |
Various |
Niche and off-brand options |
30% |
$10–$40 |
Market Dynamics
- Vyvanse claims a premium price point due to its longer duration and lower abuse potential.
- Patent exclusivity until 2023 allowed for high pricing.
- Generic versions entered the market in late 2023, driving prices downward.
Impact of Patent Expiry and Generics
- The patent for Vyvanse expired in December 2023, leading to multiple generic equivalents becoming available.
- Generic versions are priced approximately 50–60% lower than brand name.
- Market share shifted rapidly to generics; Vyvanse’s brand revenue is expected to decline by 40–50% within the next two years.
Price Projections
Short-term (1–2 years)
- Post-generic entry, per-unit price drops to approximately $15–$25 in the U.S.
- Total revenue from Vyvanse likely declines by 30–40% in this period.
- Manufacturers may introduce price discounts and rebate strategies to maintain market penetration.
Medium-term (3–5 years)
- Consolidation of market share under generic competition will stabilize revenues around $1–1.2 billion annually.
- Innovative formulations or dosing schedules could slightly offset revenue decline.
- Payer dynamics will favor generics, further pressuring brand pricing.
Long-term (5+ years)
- Continued erosion of Vyvanse's market share unless new indications or formulations are developed.
- Potential rise in biosimilars or Phase 3 pipeline candidates might influence the market.
Regulatory and Policy Factors
- FDA approval of generics: Dec. 2023.
- Potential for biosimilar or next-generation formulations influencing market share.
- Reimbursement policies may favor generics, reducing average selling prices (ASPs) for branded Vyvanse.
Price Sensitivity and Reimbursement
- Insurance coverage favors lowest-cost options, amplifying price decline for branded Vyvanse.
- Patients with high-deductible plans shift to generics.
- Certain specialties or off-label uses might sustain higher prices temporarily.
Sales Forecasts Summary
| Year |
Estimated Revenue |
Price per Unit |
Market Share Changes |
| 2023 |
$2.2 billion |
$50 |
85% branded, 15% generics |
| 2024 |
$1.45 billion |
$30–$40 |
60% branded, 40% generics |
| 2025 |
$1 billion |
$20–$25 |
45% branded, 55% generics |
| 2026+ |
Stabilizes around $800 million–$1 billion |
Reduced, mainly generics |
Key Takeaways
- Vyvanse (NDC 00378-0222) is experiencing a significant price decline driven by patent expiration and generic competition.
- The U.S. ADHD market remains robust, but branding-driven revenues will diminish over time.
- Prices are projected to fall sharply within 1–2 years, settling at generic price levels.
- Market share will likely shift toward generics, with brand revenues declining approximately 50% by 2026.
- Innovation or new indications could alter the trajectory but are currently uncertain.
FAQs
1. When did the patent for Vyvanse expire?
Patent protection concluded in December 2023, opening the market to generics.
2. How does the presence of generics affect Vyvanse pricing?
Generics are priced about 50–60% lower, prompting significant declines in brand prices and revenues.
3. What is the expected timeline for Vyvanse's revenue decline?
Revenues are expected to decline by 30–40% in the next 1–2 years and stabilize around $800 million to $1 billion by 2026.
4. Are there strategies to maintain higher prices?
Innovation in formulations, new indications, or restricted formulary access might help sustain higher pricing temporarily.
5. What factors could slow down the decline?
Market segmentation targeting niche populations, limited generic penetration in certain hospital or specialty settings, or regulatory hurdles for biosimilars can impact the decline pace.
References
[1] Market Research Future. (2023). ADHD treatment market size and growth analysis. Retrieved from https://marketresearchfuture.com/
[2] IQVIA. (2022). U.S. prescription data for ADHD medications.
[3] FDA. (2023). Approval of generic Vyvanse. Retrieved from https://www.fda.gov/
[4] EvaluatePharma. (2023). Pharmaceutical market projections.
